

# Index

## 0–9

- 3' untranslated region (3' UTR), 39
- 7-gene operon, 96

## A

- Acquarium tank granuloma. *See* Fish tank granuloma
- Ad5-vectored vaccines, 271–272
- Ad5. *See* Human type 5 adenovirus
- ADE. *See* Antibody-dependent enhancement
- Advanced glycation end products (AGE), 98
- Aerosol infection, 149
- Ag85. *See* Antigen 85
- AGE. *See* Advanced glycation end products
- Aging
  - See also* Tuberculosis (TB)
  - immunological impairment, 19
  - immunological susceptibility to TB, 18
  - impact on global TB incidence, 19
  - impact upon immune function, 17
    - immunosenescence, 18
    - pre-antibiotic studies, 18
  - impact upon TB epidemiology, 18
    - effects, 19
    - Mycobacterium tuberculosis*, 18
    - meta-analysis, 18
    - world's population, 17
- A/J mouse strains, 35
- Alcohol, 23
  - See also* Tuberculosis (TB)
  - immunological impairment, 24
  - impact on
    - immune function, 23
    - tuberculosis risk, 23–24
- Alcohol consumption, 24
- ALOX5. *See* Arachidonate 5-lipoxygenase
- $\alpha$ -galactosylceramide ( $\alpha$ GalCer), 205
- Alveolar macrophage, 104
- AM-TT. *See* Arabinomannan-221 tetanus toxoid
- Analysis of variance (ANOVA), 36
- ANOVA. *See* Analysis of variance
- Anti-apoptotic Mtb genes, 96
- Antibodies, 231, 234
- Antibody-dependent enhancement (ADE), 233
- Antigen 85 (Ag85), 145
- Antigen presentation, 229–230
  - by CD1a, 183, 184f
    - activated saposins, 184
    - anti-mycobacterial immunity, 184–185
    - AP binding motifs and cycles, 184
    - crystal structure, 185
    - endoplasmic reticulum, 184
    - mycobactins and molecules, 185
    - T cell clones and polyclonal T cell, 185
  - by CD1b, 184f, 185
    - acidic pH, 186–187
    - autoreactive T cells, 186
    - crystal structure, 185, 186
    - endosomes and lysosomes, 187
    - long chain glucose monomycolate, 186
    - long chain self-lipids, 186

**A** (*cont.*)

- sampling antigens, 186
- T cell clones, 187
- by CD1c, 184*f*, 187
  - antigenic compounds, 187
  - crystal structure, 188
  - hydrophobic binding pockets, 188
  - mannosyl phosphomycoketide, 187
  - in mediating T cell responses, 187
- priming of T cells, 230–231
- vaccination strategies, 230
- Antigen-presenting cell (APC), 148
- Antigen-specific CD8<sup>+</sup> T cells, 147
- Antigen-specific T cells, 269
  - respiratory mucosal boost strategies, 270*f*
- Antigens, 145
  - antigenic proteins, 88
  - recognition of, 207
    - $\alpha$ GalCer variants, 207
    - cellular glycosphingolipids, 208
    - KN7000, 207
    - stimulating lipids, 208, 209–210
    - synthetic glycolipid antigens, 207, 208*f*
- APC. *See* Antigen-presenting cell
- ApoE. *See* Apolipoprotein E
- Apolipoprotein E (ApoE), 202
- Apoptosis, 104
  - apoptosis-inducing proteins, 107
  - extrinsic pathway, 105, 106–107
  - intrinsic pathway, 107
  - of *Mycobacterium marinum*-infected granuloma macrophages, 256
  - macrophage, 258
  - Mycobacterium*-induced, 257
  - virulent mycobacteria, 256
- Arabinomannan-221 tetanus toxoid (AM-TT), 273
- Arachidonate 5-lipoxygenase (ALOX5), 39
  - LTB<sub>4</sub> activity, 39, 40
  - LX and LT, 39
  - non-synonymous exonic variant, 40
- Arachidonic acid, 109
- Autophagy, 39

**B**

- B cells
  - See also Mycobacterium tuberculosis* (*M. tuberculosis*)
  - antigen presentation, 229–230
    - priming of T cells, 230–231
    - vaccination strategies, 230
  - cytokine production, 231–232
  - exclusion of role for, 227

- Fc $\gamma$ R engagement, 232
  - immunization protocols, 232–233
  - Sindbis virus-based vectors, 233
- in germinal center-like structures, 240–241
- interaction with T cells, 229
- modulating immune responses to *Mycobacterium tuberculosis*, 228–229
- regulation of effector cells, 233–234
- role in immune response development, 236
  - antibody-antigen immune complex mechanism, 239*f*
  - B cell-deficient mice infection, 236
  - B cells and humoral immunity effect, 239–240
  - granuloma, 238*f*, 239
  - immune complex formation, 238
  - immune complex interaction with Fc $\gamma$ Rs, 237–238
  - morbidity and mortality of infection, 240
  - murine TB model involvement, 237
- B effector-1 (Be1), 231
- Bacille Calmette-Guérin (BCG), 82, 188, 226, 268
  - BCG-osis, 48
  - disease, 63
  - infection, 35
  - Mycobacterium bovis*, 256
  - vaccines, 48
- Bacille de Calmette et Guérin. *See* Bacille Calmette-Guérin (BCG)
- Bacterial load, 36
- Bacterial proliferation, 258
- BCG. *See* Bacille Calmette-Guérin
- Bcl-2 family protein, 107
- Be1. *See* B effector-1
- $\beta$ -glucosylceramide ( $\beta$ GlcCer), 211
- $\beta$ 2-microglobulin ( $\beta$ 2m), 143
- BLIMP1. *See* Bone homeostasis genes
- Blocking plasma membrane repair
  - Ca<sup>++</sup> sensors, 112
  - ESX-1, 112
  - intracellular mycobacterial replication, 113
  - Mtb*, 112
  - PGE<sub>2</sub>, 112–113
  - plasma membrane resealing, 112
- Bone homeostasis genes (BLIMP1), 62
- Bos taurus. *See* Cattle
- Brefeldin A, 112

**C**

- Ca<sup>++</sup> sensors, 112
- Calnexin (CNX), 203*f*

- Calreticulin (CRT), 203*f*  
 Candidate gene studies, 34  
 Case-control studies, 3–4  
 Caseum, 252, 258  
 Caspase 3, 108  
 Caspase 8, 106  
 Cattle, 188  
*Cavia porcellus*. See guinea pigs, 188  
 CD. See Cluster of differentiation  
 CD1 antigen presentation  
   CD1d protein, 200  
     expression, 201–202  
     with MHC class I proteins, 201  
     pathogens influence, 202  
     structure, 201  
   protein family, 200  
 CD1 proteins  
   cellular expression  
     CD1d-restricted invariant NKT cells, 182–183  
     human and mouse CD1 proteins, 183  
     human CD1a, CD1b, and CD1c, 182  
     subcellular trafficking, 183  
   cytoplasmic tail, 183  
   function of group 1 CD  
     cattle, 188  
     CD1b-restricted responses, 189  
     guinea pigs species, 188  
     with *Mycobacterium tuberculosis*, 189  
     polyclonal T cells, 188–189  
     using tetramers, 189–190  
     using unloaded CD1b tetramer, 190  
     in vitro generated data, 188  
   group 1 and group 2, 181–182  
   group 1 CD1 versus group 2 CD1, 182  
   isoforms and genes, 182  
   published research, 182  
 CD1a protein, 183, 184*f*  
   activated saposins, 184  
   anti-mycobacterial immunity, 184–185  
   AP binding motifs and cycles, 184  
   crystal structure, 185  
   endoplasmic reticulum, 184  
   mycobactins and molecules, 185  
   T cell clones and polyclonal T cell, 185  
 CD1b protein, 184*f*, 185  
   acidic pH, 186–187  
   autoreactive T cells, 186  
   crystal structure, 185–186  
   endosomes and lysosomes, 187  
   long chain glucose monomycolate, 186  
   long chain self-lipids, 186  
   sampling antigens, 186  
   T cell clones, 187  
 CD1c protein, 184*f*, 185  
   antigenic compounds, 187  
   crystal structure, 188  
   hydrophobic binding pockets, 188  
   mannosyl phosphomycoketide, 187  
   in mediating T cell responses, 187  
 CD1d protein, 200  
   expression, 201–202  
   lipid antigen loading, 202  
     ApoE, 202  
     MTP, 203  
     NPC2 protein, 204  
     synthesis, 203*f*  
     trafficking, 203*f*  
   with MHC class I proteins, 201  
   pathogens influence, 202  
   structure, 201  
   T cell populations restriction, 204  
     iNKT cells, 204, 205  
     invariant TCR $\alpha$  chain, 204, 205  
     type I NKT cells, 204  
     type II NKT cells, 205  
     type III NKT cells, 205  
 CD1d tetramers, 182  
 CD1d-restricted NKT cells, 185  
 CD4<sup>+</sup> T cells, 142  
 CD8<sup>+</sup> T cells, 142, 212  
   antigen presentation pathways, 151*f*  
   CFP10 and ESAT6, 150  
   class I MHC processing pathway, 151–152  
   cross-priming  
     class II MHC pathway, 148  
     DC and APC, 148  
     endocytic system, 150  
     *Mycobacterium tuberculosis* antigens, 149–150  
     mycobacterial antigens, 149  
     prime ESAT6-specific CD4<sup>+</sup> T cells, 149  
 CTL activity, 154  
 cytokine production, 154  
 dramatic heterogeneity, 156  
 effector functions  
   cytokine production, 153  
   IFN $\gamma$  antibacterial activity, 152–153  
   *Mycobacterium tuberculosis* infection, 152  
   protection against tuberculosis, 153  
 ESX-1 complex, 150  
 genetic models, 155  
 to immunity against TB  
    $\beta$ 2m, 143  
   antibody-mediated depletion, 143  
   bacterial growth, 144

**C (cont.)**

- CD4<sup>+</sup> T cells, 143–144
- class I MHC-restricted, 143
- contribution, 144
- infected macrophages, 155
- Mycobacterium tuberculosis* protein antigen secretion, 150
- mycobacterial antigens
  - CFP10-specific CD8<sup>+</sup> T cells, 145
  - class I MHC, 144
  - cross-presentation process, 144
  - ESAT6-related proteins, 146–147
  - ESX-1, 146
  - immunodominant epitopes, 146
  - Mycobacterium tuberculosis* enome, 145
  - macrophage infection, 145
  - priming, 114
  - protection, 155
  - target cell lysis mechanisms, 154f
  - uninfected DC, 152
- Cell death, 108, 256–257
  - bacterial proliferation, 258
  - caseum, 258
  - ESAT-6-induced apoptotic, 257
  - macrophage necrosis, 258
  - Mycobacterium*-induced apoptosis, 257
  - protective neutrophils role, 257–258
- Cell surface molecules, 167
- Cell-mediated immunity, 226
- Cellular glycosphingolipids, 208
- CFP10. *See* Culture filtrate protein 10
- CFP10-specific CD8<sup>+</sup> T cells, 145
- CFU. *See* Colony forming unit
- Chemokines, 274
  - chemokine-related genes, 36
  - TLR2, 38
- ChIP. *See* Chromatin immunoprecipitation
- Chromatin immunoprecipitation (ChIP), 65
- Chronic disease, 24
  - See also* Tuberculosis (TB)
  - impact of chronic illness, 24, 25
  - kidney disease, 24, 25
- Chronic obstructive pulmonary disease (COPD), 18, 25
- Chronic T cell response
  - IL-12-related cytokines impact
    - balanced cytokine responses, 126f
    - IL-17-producing cells, 125
    - lung stromal cells, 125
    - pathological consequences, 126
- CI. *See* Confidence interval
- Class I MHC processing pathway, 145, 151–152

- Cluster of differentiation (CD), 200
- CNX. *See* Calnexin
- Colony forming unit (CFU), 212
- Confidence interval (CI), 38
- COPD. *See* Chronic obstructive pulmonary disease
- COX. *See* Cyclooxygenases
- cPLA<sub>2</sub>- $\gamma$ . *See* Cytosolic phospholipase A<sub>2</sub>- $\gamma$
- Cross-presentation process, 144
- CRT. *See* Calreticulin
- Culture filtrate protein 10 (CFP10), 112, 145
- Cyclooxygenases (COX), 109
- Cytokines, 231, 234, 237
  - effector B cells, 231
  - inflammatory, 202
  - production, 154, 231–232
- Cytosolic components, 39
- Cytosolic phospholipase A<sub>2</sub>- $\gamma$  (cPLA<sub>2</sub>- $\gamma$ ), 109

**D**

- D2 mice. *See* DBA/2 mice
- DBA/2 mice (D2 mice), 61
- DC. *See* Dendritic cell
- DDA. *See* Dimethyldioctadecylammonium bromide
- Dendritic cell (DC), 123, 148, 211, 252
- Diabetes, 11
  - See also* Alcohol; Chronic disease; Human immunodeficiency virus (HIV)
  - diabetic control affect, 12
  - double-burden, 11
  - and risk of TB, 11–12
  - and treatment outcomes, 13–14
- Dimethyldioctadecylammonium bromide (DDA), 271
- dLN. *See* Draining lymph node
- Double-negative cells, 190
- Draining lymph node (dLN), 123
- Drug-tolerant mycobacteria, 260

**E**

- Early secretory antigen target-6 (ESAT6), 112, 145
  - ESAT-6-induced apoptotic cell death, 257
  - ESAT6-related proteins, 146–147
- East-Asian strains, 34
- EBI3. *See* Epstein-Barr Virus-Induced gene 3
- Effector T cells, 269
- Ehrlichia chaffeensis* study, 227
- Eicosanoids, 115, 130
  - BCG or *Mtb*, 116
  - caspase 8 and caspase 9, 115–116

LXA<sub>4</sub>, 115  
*Mtb*-infected macrophages, 116  
 prostanoids, 115  
 TB10.4 antigen, 115  
*eis* gene. *See* Enhanced intracellular survival gene  
 Endoplasmic reticulum (ER), 144  
 Enhanced intracellular survival gene (*eis* gene), 95  
 Epidemiological evidence, key terms, 4  
   association, 4  
   impact, 4  
   prevalence, 4  
   risk, 4  
 Epithelioid cells, 252  
 Epstein-Barr Virus-Induced gene 3 (EBI3), 123  
 eQTLs. *See* Stable expression quantitative trait loci  
 ER. *See* Endoplasmic reticulum  
 ESAT-6 secretion system 1 (ESX-1), 112, 127  
 ESAT6. *See* Early secretory antigen target-6  
 ESX-1 secretion system, 97  
 ESX-1. *See* ESAT-6 secretion system 1  
 ESX-5 type VII secretion system, 98  
 esxA component, 97  
 Euro-American strains, 38  
 Extrinsic pathway, 105, 106–107

## F

Fatty acid amide hydrolase (FAAH), 204  
 Fcc receptor engagement (FcγR engagement), 232  
   immunization protocols, 232–233  
   Sindbis virus-based vectors, 233  
 FcγR engagement. *See* Fcc receptor engagement  
*Fizz1* marker, 210  
 Fish tank granuloma, 253  
 Foxp3<sup>+</sup> T reg cells, 167

## G

Gbp. *See* Guanylate binding proteins  
 Genetic-based TB vaccines, 272  
 Genetically deficient (-/-), 63  
 Genome-level data, 88  
 Genome-level interrogation, 88  
 Granulomas, 252  
   *See also* Tuberculous granuloma  
   molecular mechanism for, 258–259

  promoting dissemination of infection, 259–260  
 Group1 CD1-restricted T cells  
   using antigen-loaded tetramers, 191  
   candidate effector functions, 191  
   chemical diversity, 190  
   double-negative cells, 190–191  
   ILT4, 190  
   MHC class I-and II-restricted T cells, 190  
   possibilities, 192  
 Guanylate binding proteins (Gbp), 66  
 Guinea pigs, 188

## H

HBHA. *See* Heparin-binding hemagglutinin  
 Heat-stable antigen (HSA), 205  
*Heligomosomoides polygyrus* (*H. polygyrus*), 231  
 Hematological analysis, 64  
 Heparin-binding hemagglutinin (HBHA), 98  
 Heterogeneity, 156  
 HGT. *See* Horizontal gene transfer  
 Hidden hunger. *See* Micronutrient deficiency  
 HIV/tuberculosis co-infection mortality, 16  
 Horizontal gene transfer (HGT), 84  
 Host cell death induction  
   for apoptosis/necrosis induction, 99  
   ESX-5 locus and PE\_PGRS33, 98  
   esxA (*esat-6*) component, 97–98  
   HBHA, 98  
   OppABCD, 98, 99  
 Host cell death inhibition  
   *nuoG* and *eis* gene, 95  
   protein kinase E, 95–96  
   *Rv3364c* and *Rv3654c*, 96, 97  
   superoxide dismutase A, 94  
 Host cell proteins, 97  
 Host–pathogen specificity  
   in A/J and C57BL/6J mice, 35  
   mycobacteria, 36  
 HSA. *See* Heat-stable antigen  
 Hsp70 molecules, 108  
 Hsp90 molecules, 108  
 Human CD8<sup>+</sup> T cells, 155  
 Human immunodeficiency virus (HIV)  
   *See also* Tuberculosis (TB)  
   HIV-related mortality, 15  
   HIV/tuberculosis co-infection, 16  
   impact, 16–17  
   infections  
     and AIDS-related illnesses, 14–15  
     prevalence estimation, 17f

**H** (*cont.*)

- mechanism, 15
- PLHIV, 14–15
- prevalence, 14
- progression to TB disease
  - HIV-infected patients, 15–16
  - PLHIV, 15
  - risk of acquiring TB, 16
  - susceptibility, 15
  - uninfected population, 15
- and susceptibility to LTBI, 16
- Human macrophages, 97
- Human type 5 adenovirus (Ad5), 271
- Humoral immune response
  - antibodies role, 227–228
  - in defense against *M. tuberculosis*, 226–227
  - exclusion of role for, 227
- Humoral immunity, 227, 234
  - effect on immunopathology development, 239
  - Fc $\gamma$ R engagement, 232
  - immune response against invading microbes, 229
  - multifunctionality, 235
  - for optimal clearance and vaccine efficacy, 228
- Hydrophobic binding pockets, 188

**I**

- IDO.3-dioxygenase *See* Indoleamine 2
- IFN. *See* Interferon
- IFN cytokine family
  - See also* IL-12 family
  - antigen-specific CD4 T cells, 130–131
  - effector function, 131
  - IFN $\gamma$  role, 130
- IL-10 and immunosuppressive cytokines
  - CBA, 134
  - IL-27 role in, 134
  - immunosuppressive cytokines, 135
  - mycobacteria, 134–135
  - N. brasiliensis*, 135
  - pulmonary fibrosis, 135
- IL-17 and TH17-related cytokines
  - CXCR3-ligating chemokines, 133
  - extracellular and intracellular pathogens, 133
  - inflammatory programs, 133
  - mycobacterial infections, 134
  - neutrophil recruitment, 133
- immunoregulatory properties
  - human tuberculosis, 133
  - IL-1  $\alpha$  and IL-1 $\beta$  cytokines, 132
  - Mycobacterium tuberculosis*-infected mice, 132
  - mycobacterial infection, 133
  - receptor-deficient mice, 132
  - TANK-binding kinase 1, 132
- in inflammatory environment
  - anti-inflammatory roles, 132
  - cell survival, 132
  - IFN $\gamma$  signaling and predispose, 126f, 131
  - T cells, 131
- IFN-inducible GTPase superfamily, 66
- IFN $\gamma$ . *See* Interferon- $\gamma$
- Ig-like transcript 4 (ILT4), 190
- iGb3. *See* Isoglobotrihexosylceramide
- IL. *See* Interleukin
- IL-1 cytokine family
  - cytokines, 127
  - IL-18 role, 129
  - IL-1 $\alpha$  and IL-1 $\beta$  role
    - human disease, 128–129
    - IFN $\gamma$ , 128
    - IL-17 production, 128
  - IL-1 $\beta$  production regulation
    - ESX-1, 127
    - mycobacterial infection, 127
    - Mycobacterium leprae*, 128
    - Mycobacterium tuberculosis*, 127
    - pro-IL-1 $\beta$ , 127–128
  - IL-33, 127
- IL-12 family, 123
  - in chronic T cell response, 125
    - balanced cytokine responses, 126f
    - IL-17-producing cells, 125
    - lung stromal cells, 125
    - pathological consequences, 126
- EBI3, 123
- IL-12p40, 48
- IL-12p70, 123
  - in initiation of acquired immunity
    - cytokines, 124f
    - IFN $\gamma$  response, 123, 124
    - IL-12p70, 123
    - IL-27, 124–125
    - Mycobacterium tuberculosis* infections, 123
    - mycobacterial infection, 124
- IL-17-related cytokines
  - CXCR3-ligating chemokines, 133
  - extracellular and intracellular pathogens, 133
  - inflammatory programs, 133
  - mycobacterial infections, 134

- neutrophil recruitment, 133
  - ILT4. *See* Ig-like transcript 4
  - Immune dys-regulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX), 167
  - Immune response, 122
  - Immunity, 6
  - Immunity-related GTPase M (IRGM), 39
  - Immunodominant epitopes, 146
  - Immunological disease impact sources, 3–4
  - Immunological impairment causes, 3
  - Immunological risk factors, 2
  - Immunosenescence, 18
  - Immunosuppressive cytokines, 134–135
  - Inbred strains, 60
  - Indoleamine 2, 3-dioxygenase (IDO), 125
  - Indoor air pollution
    - impair immune function, 20
    - latent TB infection, 21
    - materials, 20
    - passive smoking, 22
    - at population level, 22
    - and TB, 22
    - TST, 20
  - Infection with virulent mycobacteria
    - BCG vaccines, 48
    - BCG-osis, 48
    - IRF8, 58
    - Nramp1* gene, 58
    - T cell function, 48, 58
  - Inhibitory RNA (RNAi), 65
  - iNKT cells. *See* Invariant natural killer T cells
  - Innate cytokine response, 122
  - Interferon (IFN), 122
    - CD4 T cells, 130–131
  - Interferon Regulatory Factor* (IRF8), 62, 64
  - Interferon regulatory factor 8 (IRF8), 58, 62–63
    - BXH2 mouse strain, 61
    - IL-12p40, 62
    - IRF1, 62
    - Legionella pneumophila*, 61–62
  - Interferon Stimulated Response Elements (ISRE), 62
  - Interferon- $\gamma$  (IFN $\gamma$ ), 152–153
  - Interleukin (IL), 231
    - IL-10 cytokines, 134–135
    - IL-27, 124–125
    - IL-35, 123
  - Intracellular pathogen resistance 1 (Ipr1 gene), 60
  - Intrinsic pathway, 107
  - Invariant natural killer T cells (iNKT cells), 204, 205
    - See also* CD1d protein
    - activation mechanisms, 210
      - $\alpha$ GalCer-induced activation, 211
      - indirect pathway, 211
      - TCR binding promiscuity, 211
      - X-ray crystallographic studies, 210
    - antigens recognition, 207
      - $\alpha$ GalCer variants, 207
      - cellular glycosphingolipids, 208
      - KN7000, 207
      - stimulating lipids, 208, 209–210
      - synthetic glycolipid antigens, 207, 208f
    - development, 205–206
    - direct and indirect pathways, 209f
    - frequency, 206
    - functions, 206
    - insights from mouse models of TB, 212–213
      - role in mycobacterial infection, 211–212
      - studies in human tuberculosis, 213
      - therapeutic opportunities, 214
  - IPEX. *See* Immune dys-regulation, polyendocrinopathy, enteropathy, X-linked syndrome
  - Ipr1 gene. *See* Intracellular pathogen resistance 1
  - IRF1, 63
  - IRF8 deficiency, 45
    - in humans
      - BCG disease, 63–64
      - DNA-binding domain, 64
      - hematological analysis, 64
      - in ontogeny, 64
      - T80 variant, 64
    - in myeloid cells
      - ChIP-chip, 65
      - intracellular pathogens, 65
      - siRNA knock-down samples, 65
      - THP-1 cells, 66
      - Tlr4*, 65–66
  - IRF8. *See* Interferon Regulatory Factor; Interferon regulatory factor 8
  - IRGM. *See* Immunity-related GTPase M
  - IRGM-261TT genotype, 39
  - Isoglobotrihexosylceramide (iGb3), 208
  - ISRE. *See* Interferon Stimulated Response Elements
- ## J
- J $\alpha$ 18 gene, 205
  - J $\alpha$ 18 knockout mouse, 205

**K**

- K108R, 64  
 KN7000, 207  
 Knockout. *See* Genetically deficient (-/-)

**L**

- Latent tuberculosis infection (LTBI), 2, 5  
 LC3. *See* Light chain 3  
 LDL. *See* Low density lipoprotein  
 LDL receptor (LDLR), 203f  
 LDLN. *See* Lung draining lymph nodes  
 LDLR. *See* LDL receptor  
*Legionella pneumophila* (*L. pneumophila*), 61–62  
*Leishmania donovani* (*L. donovani*), 58  
*Leishmania*-infected dendritic cells, 168  
 Leukotriene A<sub>4</sub> hydrolase (LTA4H), 111, 130  
 Leukotriene B<sub>4</sub> synthesis (LTB<sub>4</sub> synthesis), 39, 111  
 Leukotrienes (LT), 39  
 Light chain 3 (LC3), 39  
 Linkage genome scans, 37  
 Lipoxin A<sub>4</sub> (LXA<sub>4</sub>), 109  
 Lipoxins (LX), 39, 111  
 5-lipoxygenase (5-LO). *See* Arachidonate 5-Lipoxygenase (ALOX5)  
*Listeria monocytogenes* infection, 202  
 LN. *See* Lymph node  
 Long-lived protective immunity, 142  
 Low density lipoprotein (LDL), 203f  
 LT. *See* Leukotrienes  
 LTA4H. *See* Leukotriene A<sub>4</sub> hydrolase  
 LTB<sub>4</sub> synthesis. *See* Leukotriene B<sub>4</sub> synthesis  
 LTBI. *See* Latent tuberculosis infection  
 Lung, 168  
   interstitium, 269  
   *M. tb* immune control in, 270  
 Lung draining lymph nodes (LDLN), 166  
 LX. *See* Lipoxins  
 LX<sub>4</sub>A. *See* Lipoxin A<sub>4</sub>  
 Lymph node (LN), 46, 114

**M**

- Macrophage phagocyte oxidase (NOX2), 95  
 Macrophages, 255, 256  
   apoptosis, 105  
   death pathway manipulation, 104  
   granuloma, 256  
   liver-resident, 256  
   *Mycobacterium tuberculosis*-infected, 257  
   mature, 252  
   necrosis, 258

- Major histocompatibility complex (MHC), 200  
 Malnutrition, 5, 10  
   *See also* Diabetes  
   cycle, 7f  
   evidence for vitamin supplementation in TB, 9–10  
   global burden, 5–6  
   impact upon tuberculosis, 10–11  
   mechanism, 6  
   risk, 6  
     association, 6, 7  
     beneficial impact, 8  
     BMI, 8  
     ecological studies, 7  
     TB incidence, 7–8  
     tuberculosis, 6  
   and TB mortality, 10  
   vitamin deficiency and TB  
     vitamin A, 9  
     vitamin C, 9  
     vitamin D, 8–9  
 Mannose-binding lectin (MBL), 40  
 Matrix metalloproteinase 9 (MMP9), 258, 259  
 MBL. *See* Mannose-binding lectin  
 MDR disease. *See* Multi-drug-resistant disease  
 Mendelian Susceptibility to Mycobacterial Diseases (MSMD), 46, 48  
 Meningeal tuberculosis, 38  
 Methylglyoxal (MG), 98  
 MG. *See* Methylglyoxal  
 MHC. *See* Major histocompatibility complex  
 MHC class I proteins, 200, 201  
 Micronutrient deficiency, 6  
 Micronutrients, 8  
 Microsomal triglyceride transfer protein (MTP), 203f  
 Millennium Villages program, 11  
 Mitochondrial damage  
   Bcl-2 family protein, 107  
   effector molecules, 108  
   eicosanoid biosynthetic pathways, 109  
   gene expression profiling, 109  
   Hsp70 and Hsp90, 108  
   irreversible MPT, 107  
   MOMP and MPT, 107  
   pro-apoptotic Bcl-2 protein BAX, 108  
 Mitochondrial outer membrane permeabilization (MOMP), 107  
 Mitochondrial permeability transition (MPT), 107, 111  
 MMP9. *See* Matrix metalloproteinase 9  
 MNC. *See* Mononuclear cells  
 MOMP. *See* Mitochondrial outer membrane permeabilization



- Mononuclear cells (MNC), 64
- Mouse genetic studies, 37
- Mouse strains  
 BXH, 62  
 BXH2, 61  
 C57BL/6, 61  
 C57BL/6J, 35
- MPT. *See* Mitochondrial permeability transition
- MSMD. *See* Mendelian Susceptibility to Mycobacterial Diseases
- MTB. *See* *Mycobacterium tuberculosis* (*M. tuberculosis*)
- Mtb-infected macrophage  
 BCG-infected macrophages, 114  
 CD8+ T cell priming, 114  
 cell death, 115  
 extracellular vesicles, 114  
 mycobacterial antigens, 113
- Mtb*-infected macrophage death modality modulation  
 bacterial factors, 109  
 lipoxins, 111  
 LTA4H gene and mutant, 111, 112  
*Mycobacterium bovis* strain BCG, 110  
*Mtb*-infected macrophages, 111  
 PGE<sub>2</sub> and LXA<sub>4</sub> production, 110<sup>f</sup>  
 prostanoid receptors, 109, 110  
 virulent *Mtb* strains, 111
- MTP. *See* Microsomal triglyceride transfer protein
- Multi-drug-resistant disease (MDR disease), 13
- Multidrug-resistant strains, 104
- Murine macrophages, 104
- Mus molossinus*, 58
- Mycobacteria, 97, 134, 257  
 drug-tolerant, 260  
 pathogenic, 255  
 virulent, 256
- Mycobacterial antigens  
 CFP10-specific CD8<sup>+</sup> T cells, 145  
 class IMHC, 144  
 cross-presentation process, 144  
 ESAT6-related proteins, 146–147  
 ESX-1, 146  
 extreme immunodominance  
 antigen-specific T cells, 147  
 naïve T cells repertoire, 148  
 pulmonary CD8<sup>+</sup> T cells responses, 147  
 tetramer bound T cells, 148  
 immunodominant epitopes, 146  
*Mycobacterium tuberculosis* genome, 145  
*Mycobacterium tuberculosis* protein antigens, 145  
 macrophage infection, 145
- Mycobacterial control  
 IL-1 $\alpha$  role  
 human disease, 128–129  
 IFN $\gamma$ , 128  
 IL-17 production, 128  
 IL-1 $\beta$  role  
 human disease, 128–129  
 IFN $\gamma$ , 128  
 IL-17 production, 128
- Mycobacterial infection, 33
- Mycobacterial species, 46
- Mycobacterial strain specificity  
 A/J and C57BL/6J mouse strains, 35  
 ALOX5, 39–40  
 using ANOVA, 36  
 biological phenotypes, 35–36  
 CFU and cytokines, 36  
 formal and direct evidence, 35  
 in genetic control of infection and disease, 37  
 infectious process, 37  
 RC strains, 37  
 SLC11A1 and NRAMP1, 38–39  
 toll-like receptors, 38  
 IRGM, 39  
*Mycobacterium tuberculosis*, 35  
 MBL2 variants, 40  
 mycobacterial-related effects, 36
- Mycobacterium avium* intracellular complex, 84
- Mycobacterium africanum* (*M. africanum*), 34, 82
- Mycobacterium bovis* (*M. bovis*), 226
- Mycobacterium* genus  
 environmental organisms, 84  
 HGT, 84–85  
 in humans, 83, 84  
 M. kansasii, 85  
 NTM species, 83  
 perspectives, 84  
 phylogenetic representation, 83<sup>f</sup>  
 rapid-growing organisms, 83
- Mycobacterium kansasii* (*M. kansasii*), 88–89
- Mycobacterium marinum* (*M. marinum*), 46, 253  
 infection, 255  
 trafficking in frogs and zebrafish, 254
- Mycobacterium marinum*/*Mycobacterium ulcerans* complex, 84

**M (cont.)**

*Mycobacterium tuberculosis* (*M. tuberculosis*),  
 5, 34, 46, 82, 93, 104, 127, 142, 226, 268  
 alveolar macrophage, 104  
 ancient Out-of-Africa migrations, 85–86  
 antibodies role, 227–228  
 antibody-mediated immunity, 235  
 antibody-mediated response role, 234–235  
 antigen-expressing system, 271  
 apoptosis pathways, 105, 106*f*  
 for apoptosis/necrosis induction, 99*t*  
 B cells modulating immune responses, 228–229  
 BCG, 35  
 cell-mediated immunity role, 226  
 D2 mice, 61  
 disease in humans, 82  
 epidemiological data, 59  
 evolution, 85  
 evolutionary paradigm, 86, 87  
 genes important for apoptosis inhibition, 96*t*  
 genetic factors, 59  
 genome scan, 60  
 global phylogeny, 86*f*  
 HIV/AIDS, 87  
 human genetic studies, 37  
 humoral immune response in defense against, 226–227  
 immune control in lung, 270  
 immune response, 166  
 inbred strains, 60  
 infected macrophages, 104–105  
 infection  
   ADE, 233, 234  
   in BCG-immunized hosts, 269  
   in mice, 233, 234  
   in non-immunized hosts, 269  
   respiratory mucosal boost strategies, 270*f*  
   TB vaccination, 270  
 macrophage apoptosis, 105  
*Nramp1*/*Slc11a1* gene, 59  
 pathogen factors, 34–35  
 pathogenesis of infection with  
   activated macrophages, 46–47  
   host defense mechanisms, 47  
   impressive immune response, 47  
   INF- $\gamma$  and TNF- $\alpha$ , 46  
   key defense pathway, 47  
   MSMD, 46

  pathogen-related effects, 47–48  
   primed T cells, 46  
   TACO, 47  
 pulmonary *M.tb* infection, 269  
 response of mouse mutants to, 49–57*t*  
 strains, 34  
*Tbs1* and *Tbs2*, 60–61  
*Tlr1*, 59–60  
 virulence or susceptibility, 35  
*Mycobacterium tuberculosis* aerosol infection model, 125  
*Mycobacterium tuberculosis*-infected mice, 65  
*Mycobacterium*-induced apoptosis, 257  
 Mycobactin siderophores, 184–185

**N**  
 Natural killer cell (NK cell), 252  
 Natural killer T cells (NKT cells), 182, 200, 204  
   subsets, 204*f*  
   type I, 204  
   type II, 205  
   type III, 205  
 Natural resistance-associated macrophage protein 1 (*Nramp1*), 37, 38–39  
   effect, 59  
   gene, 58  
   *Nramp1*/*Slc11a1*, 58  
 NCS-1. *See* Neuronal calcium sensor 1  
 Necroptosis, 105  
 Necrosis, 104, 105, 258  
 NEMO. *See* NF $\kappa$ B regulator I $\kappa$ B $\gamma$   
 Neuronal calcium sensor 1 (NCS-1), 112  
 Neutrophils, 240, 257  
 NF $\kappa$ B regulator I $\kappa$ B $\gamma$  (NEMO), 48  
 Niemann-Pick type C2 protein (NPC2 protein), 204  
*Nippostrongylus brasiliensis* (*N. brasiliensis*), 135  
 NK cell. *See* Natural killer cell  
 NKT cells. *See* Natural killer T cells  
 NLRP3. *See* NOD-like receptor family, pyrin domain containing 3  
 NOD. *See* Nucleotide Oligomerization Domain  
 NOD-like receptor family, pyrin domain containing 3 (NLRP3), 127  
 Non-mycolyl lipids, 186  
 Non-reproducibility, 34  
 Non-tuberculosis mycobacterial species (NTM species), 83, 84

NOX2. *See* Macrophage phagocyte oxidase  
 NPC2 protein. *See* Niemann-Pick type C2 protein  
 Nramp1. *See* Natural resistance-associated macrophage protein 1  
 NTM species. *See* Non-tuberculosis mycobacterial species  
 Nucleotide Oligomerization Domain (NOD), 122  
 nuoG gene, 95  
 Nutrition, 6  
 Nutritional deficiencies, 6

## O

OppABCD transporter, 98, 99  
 Organism-based vaccines, 271

## P

PAF. *See* Population attributable fraction  
 PAMP. *See* Pathogen-associated molecular pattern  
 Passive smoking, 22  
 Pathogen recognition receptor (PPR), 122  
 Pathogen-associated molecular pattern (PAMP), 38  
 PC. *See* Phosphatidylcholine  
 pDC. *See* Plasmacytoid DC  
 PE. *See* Phosphatidylethanolamine  
 PE\_PGRS33 protein, 98  
 People living with HIV (PLHIV), 2, 15  
 Peptide antigen-specific T cells, 200  
 Perforin, 155  
 PG. *See* Phosphatidylglycerol  
 PGE<sub>2</sub>. *See* Prostaglandin E<sub>2</sub>  
 Phagosome maturation, 38  
 Phosphatidylcholine (PC), 203f, 207  
 Phosphatidylethanolamine (PE), 207  
 Phosphatidylglycerol (PG), 207  
 Phosphatidylinositol (PI), 207  
 Phosphatidylinositol mannoside (PIM), 186, 208, 212  
 PI. *See* Phosphatidylinositol  
 PIM. *See* Phosphatidylinositol mannoside  
 pklr. *See* Pyruvate kinase  
*pknE*. *See* Protein kinase E  
*pksl15* gene. *See* Polyketide synthase  
 Plasmacytoid DC (pDC), 62  
 PLHIV. *See* People living with HIV  
 PLN. *See* Pulmonary LN  
 Polyketide synthase (*pksl15* gene), 38  
 Population attributable fraction (PAF), 3  
 PPR. *See* Pathogen recognition receptor

Primary progressive disease, 5  
 Pro-inflammatory molecules, 38  
 Prostaglandin E<sub>2</sub> (PGE<sub>2</sub>), 109, 113  
   in fostering membrane repair, 113  
   PI3 K activation, 112–113  
   protective effect, 112  
 Prostaglandin-associated genes, 60  
 Prostanoid species, 109  
 Prostanoids, 115  
 Protein calorie malnutrition, 6  
 Protein kinase E (*pknE*), 95–96  
 Protein-associated splicing factor (PSF), 96  
 Protein-based TB vaccine formulations, 273  
 PSF. *See* Protein-associated splicing factor  
 Pulmonary fibrosis, 135  
 Pulmonary LN (PLN), 115  
 Pyroptosis, 105  
 Pyruvate kinase (*pklr*), 58

## Q

Quantitative trait loci (QTLs), 65

## R

Randomized-controlled trial design, 3  
 RC strains. *See* Recombinant congenic mouse strains  
 RDs. *See* Regions of difference  
 Reactive nitrate intermediates (RNI), 95–96  
 Reactive oxygen species (ROS), 95–96, 107  
 Receptor-interacting proteins 1 and 3 (RIP-1/3), 105  
 Recombinant congenic mouse strains (RC strains), 37  
 Regions of difference (RDs), 85  
 Regulatory T cells (Tregs), 122  
   in autoimmune disease, 167  
   Foxp3<sup>+</sup> T reg cells, 167  
   in human tuberculosis, 168  
   lung, 168  
   T reg cell frequencies, 168–169  
   T reg cell proliferation, 169  
   TB severity, 168–169  
 in infection, 168  
 in mouse model of tuberculosis, 170–171  
   using anti-CD25 antibodies, 170  
   autoimmune inflammation, 171  
   IFN- $\gamma$ -producing CD4 T cells, 170  
   *Mtb*-specific T reg cells, 171–172  
   observations, 175t  
   pathogen-specific T reg cells, 172, 173f  
   specialization, 174  
   TCR transgenic mice, 173, 174

**R** (*cont.*)

- Th1 effector cell proliferation, 170–171
- role in human TB, 169–170
- Replication-defective Ad5-based vector, 273–274
- Respiratory mucosal boost immunization, 272
  - See also* T cell geography
  - protein-based TB vaccine formulations, 273
  - replication-defective Ad5-based vector, 273–274
  - viral-vectored TB vaccines tropism, 273
- Respiratory mucosal manipulations
  - See also* T cell geography
  - “vaccineless” boost strategies, pros and cons of, 275
  - “vaccineless” creation of airway luminal T cells
    - in models of parenteral genetic-based immunization, 274
    - in parenteral BCG-immunized hosts, 274–275
- Rheumatoid arthritis, 25
- RIP-1/3. *See* Receptor-interacting proteins 1 and 3
- RNAi. *See* Inhibitory RNA
- RNI. *See* Reactive nitrate intermediates
- ROS. *See* Reactive oxygen species
- Rv3364c* gene, 96, 97
- Rv3654c* gene, 96, 97

**S**

- SAP. *See* SLAM-associated protein
- Sec61 host protein, 152
- secA2* mutant, 94
- Sindbis virus-based vectors, 233
- Single nucleotide polymorphism (SNP), 85
- SLAM-associated protein (SAP), 206
- Slc11a1* gene. *See* Solute carrier family 11 member 1
- SM. *See* Sphingomyelin
- Smoking, 25
  - See also* Indoor air pollution; Tuberculosis (TB)
  - cigarette consumption, 20
  - impacts upon immune function
    - impair immune function, 20
    - tobacco, 20
  - latent TB infection, 21
  - passive smoking, 22
  - at population level, 22
  - and susceptibility to LTBI, 20
  - and TB mortality, 21

- tobacco, 20
- and tuberculosis, 21
- vast majority, 20
- SNP. *See* Single nucleotide polymorphism
- SodA. *See* Superoxide dismutase A
- SodA-knock-down strain, 94
- Soluble molecules, 167
- Solute carrier family 11 member 1 (*Slc11a1* gene), 37, 38–39
- Spacer oligotyping, 85
- Sphingomyelin (SM), 203f
- Spoligotyping. *See* Spacer oligotyping
- sst1* gene. *See* Super-susceptibility TB
- Stable expression quantitative trait loci (eQ-TLs), 65
- Subunit vaccines, 271, 272
- Super-susceptibility TB (*sst1* gene), 60
- Superoxide dismutase A (SodA), 94
- Susceptibility/resistance spectrum, 35
- Synaptotagmin 7 (SYT7), 112
- Synthetic glycolipid antigens, 207, 208f
- SYT7. *See* Synaptotagmin 7

**T**

- T cell geography, 269
  - Ad5-vectored vaccines, 271, 272
  - M. tb* immune control in lung, 270, 271
  - M. tb* infection
    - in BCG-immunized hosts, 269
    - in non-immunized hosts, 269
    - respiratory mucosal boost strategies, 270f
    - TB vaccination, 270
  - organism-based vaccines, 271
  - subunit vaccines, 271
  - viral-vectored TB vaccines, 272
- T cell receptor (TCR), 116, 167, 182, 204
- T cells
  - embedded within B cell clusters, 241
  - heterogeneity during *M. tuberculosis* infection, 156
  - interaction with B cell, 229
  - Mtb* and LDLN, 166
  - Mtb*-infected DCs, 166
  - priming of, 230
- T helper1 cells (Th1 cells), 122
- T80 variant, 64
- TAP. *See* Transporter associated with antigen processing
- TB. *See* Tuberculosis
- TCR. *See* T cell receptor
- TDM 6'-dimycolate. *See* Trehalose-6
- Th1 cells. *See* T helper1 cells

- TH17-related cytokines  
 CXCR3-ligating chemokines, 133  
 extracellular and intracellular pathogens, 133  
 inflammatory programs, 133  
 mycobacterial infections, 134  
 neutrophil recruitment, 133
- Th2-derived cytokines, 135
- TLR. *See* Toll-like receptor
- TLR2 T597C polymorphism, 38
- TNF. *See* Tumor necrosis factor
- TNF-deficient mice, 130
- Tobacco smoking, 20
- Toll-like receptor (TLR), 38, 122
- Transporter associated with antigen processing (TAP), 143
- Tregs. *See* Regulatory T cells
- Trehalose-6,6'-dimycolate (TDM), 212
- TST. *See* Tuberculin skin test
- Tubercles. *See* Granulomas
- Tuberculin skin test (TST), 20
- Tuberculosis (TB), 1–2, 46, 82, 268  
*See also* Chronic disease; Diabetes and diabetes  
 diabetic control effect, 12  
 evidence for association, 14  
 global burden, 11  
 and risk of tuberculosis, 11–12  
 and treatment outcomes, 13–14  
 epidemiology, 2  
 granulomas, 252  
 immunological factors role, 2, 3  
 immunological impairment, 4–5  
 incidence, 2  
 iNKT cells  
 insights from mouse models of, 212–213  
 studies in human tuberculosis, 213  
 literature review, 5  
 LTBI, 2  
*Mycobacterium tuberculosis*, 226  
 malnutrition  
 global burden, 5–6  
 mechanism, 6  
 at population level, 10–11  
 and risk of tuberculosis, 6, 7–8  
 and tuberculosis mortality, 10  
 vitamin deficiency, 8–10  
 meningitis, 86  
 PLHIV, 2  
 using PubMed, 5  
 TB10.4 antigen, 115  
 zebrafish model of, 253
- Tuberculous granuloma, 252
- B cells in germinal center-like structures, 240–241  
 cell death role, 256–257  
 bacterial proliferation, 258  
 caseum, 258  
 macrophage necrosis, 258  
*Mycobacterium*-induced apoptosis, 257  
 protective neutrophils role, 257–258  
 dynamic accumulation, 256  
 epidemiological and histological evidence, 252–253  
 formation, 254–255  
 macrophage chemotactic morphology, 255  
 mature granuloma failure, 254  
 multiple immunodeficiencies, 253  
 safe-haven for mycobacteria, 254  
 three-dimensional time-lapse microscopy, 255–256  
 “walling off” bacteria, 253
- Tumor necrosis factor (TNF), 253  
 blockade therapy, 226  
 eicosanoids, 130  
 IFN $\gamma$  or IL-12p40, 129  
 mycobacterial infections, 129–130  
 using TNF blocking agents, 129  
 TNFRI, 130
- Type I IFN immunoregulatory properties  
 human tuberculosis, 133  
 IL-1  $\alpha$  and IL-1 $\beta$  cytokines, 132  
*Mycobacterium tuberculosis*-infected mice, 132  
 mycobacterial infection, 133  
 receptor-deficient mice, 132  
 TANK-binding kinase 1, 132
- U**  
 Untranslated pseudogene, 200
- V**  
 “Vaccineless” boost strategies  
 in parenteral BCG-immunized hosts, 274–275  
 in parenteral genetic-based immunization models, 274  
 respiratory mucosal, pros and cons of, 275  
 Vesicular stomatitis virus-based vaccines, 272  
 Viral-vectored TB vaccines, 272, 273  
 Virulent *Mtb* strains, 111  
 Vitamin deficiency, 8  
 evidence for vitamin supplementation in TB, 9–10  
 micronutrients, 8

**V** (*cont.*)

- vitamin A, 9
- vitamin C, 9
- vitamin D, 8–9

**W**

- “Walling off” bacteria, 253
- Wild type (WT), 113
- World Health Organization (WHO), 5, 104
- WT. *See* Wild type

**X**

- X-ray crystallographic studies, 210

**Y**

- Yml* marker, 233

**Z**

- Zebrafish model, 253
  - advantage of, 259
  - dynamic imaging studies in, 255
  - live imaging studies in, 257
- Mycobacterium marinum*-infected granuloma macrophage apoptosis, 256–257
- protective neutrophils role in, 257–258